Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2015 3
2016 2
2017 12
2018 33
2019 39
2020 37
2021 62
2022 38
2023 40
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Results by year

Filters applied: . Clear all
Page 1
Ertugliflozin for the treatment of type 2 diabetes.
Sharma R, Razdan K, Kuhad A, Kuhad A. Sharma R, et al. Drugs Today (Barc). 2019 Mar;55(3):167-175. doi: 10.1358/dot.2019.55.3.2904972. Drugs Today (Barc). 2019. PMID: 30938372 Review.
Sodium/glucose cotransporter 2 (SGLT2) is exclusively expressed in the S1 and S2 segments of proximal convoluted tubules and accounts for roughly 90% of glucose reabsorption. Ertugliflozin, a highly selective and reversible SGLT2 inhibitor, is the latest addition to the gl …
Sodium/glucose cotransporter 2 (SGLT2) is exclusively expressed in the S1 and S2 segments of proximal convoluted tubules and accounts for ro …
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714 Clinical Trial.
METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. ...CONCLUSIONS: Among patients with type …
METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic c …
Ertugliflozin for type 2 diabetes.
[No authors listed] [No authors listed] Aust Prescr. 2019 Apr;42(2):70-72. doi: 10.18773/austprescr.2019.018. Epub 2019 Feb 28. Aust Prescr. 2019. PMID: 31048942 Free PMC article. Review. No abstract available.
Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D'Addio F, Zuccotti GV, Fiorina P. Lazzaroni E, et al. Pharmacol Res. 2021 Sep;171:105782. doi: 10.1016/j.phrs.2021.105782. Epub 2021 Jul 22. Pharmacol Res. 2021. PMID: 34302978 Free article.
INTRODUCTION: Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in patients with type 2 diabetes, but lifestyle-based weig …
INTRODUCTION: Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss can significantly improve …
Ertugliflozin in the treatment of type 2 diabetes mellitus.
Marrs JC, Anderson SL. Marrs JC, et al. Drugs Context. 2020 Nov 30;9:2020-7-4. doi: 10.7573/dic.2020-7-4. eCollection 2020. Drugs Context. 2020. PMID: 33293984 Free PMC article. Review.
More than 422 million people worldwide have diabetes, with 90-95% having type 2 diabetes (T2D). Glycemic control of T2D has demonstrated reductions in microvascular complications but recent data have demonstrated improvements in macrovascular outcomes with so …
More than 422 million people worldwide have diabetes, with 90-95% having type 2 diabetes (T2D). Glycemic control of T2D …
Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
Hu J, Deng A, Zhao Y. Hu J, et al. Expert Opin Pharmacother. 2018 Nov;19(16):1841-1847. doi: 10.1080/14656566.2018.1525360. Epub 2018 Sep 24. Expert Opin Pharmacother. 2018. PMID: 30223693 Review.
Sodium-dependent glucose transporter 2 (SGLT2) inhibitors are novel, potent oral anti-diabetic agents in a beta-cell function-independent manner, inhibiting SGLT2-mediated renal glucose reabsorption and thus increasing urinary glucose excretion. Ertugliflozin (Steglatro(TM …
Sodium-dependent glucose transporter 2 (SGLT2) inhibitors are novel, potent oral anti-diabetic agents in a beta-cell function-independent ma …
Ertugliflozin for treatment of patients with Type 2 diabetes mellitus.
Yang J. Yang J. Expert Rev Clin Pharmacol. 2018 Aug;11(8):747-753. doi: 10.1080/17512433.2018.1503051. Epub 2018 Jul 31. Expert Rev Clin Pharmacol. 2018. PMID: 30025475 Review.
Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. ...Areas covered: In this paper, the mechanism of action, pharmacokinetics, clinical efficacy, safety, etc., of ertugliflozin have been introduced. Expert commentary …
Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. ...Areas covered: In this paper, …
Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Liu L, Shi FH, Xu H, Wu Y, Gu ZC, Lin HW. Liu L, et al. Front Pharmacol. 2022 Jan 20;12:752440. doi: 10.3389/fphar.2021.752440. eCollection 2021. Front Pharmacol. 2022. PMID: 35126103 Free PMC article. Review.
Objective: To evaluate the efficacy and safety of ertugliflozin in patients with type 2 diabetes. Methods: MEDLINE, EMBASE, and Cochrane Library were searched (July 31, 2021) for phase II/III randomized clinical trials, which reported the efficacy and …
Objective: To evaluate the efficacy and safety of ertugliflozin in patients with type 2 diabetes. Methods: MEDLI …
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Kelly MS, et al. Postgrad Med. 2019 Jan;131(1):31-42. doi: 10.1080/00325481.2019.1549459. Epub 2018 Nov 30. Postgrad Med. 2019. PMID: 30449220 Free article. Review.
OBJECTIVE: To review glucose-lowering efficacy and changes in renal function associated with sodium-glucose co-transporter 2 (SGLT2) inhibitors among patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). DATA SOURCES: A litera …
OBJECTIVE: To review glucose-lowering efficacy and changes in renal function associated with sodium-glucose co-transporter 2 (SGLT2) inhibit …
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CP; VERTIS CV Investigators. Cherney DZI, et al. Diabetologia. 2021 Jun;64(6):1256-1267. doi: 10.1007/s00125-021-05407-5. Epub 2021 Mar 4. Diabetologia. 2021. PMID: 33665685 Free PMC article. Clinical Trial.
METHODS: Individuals with type 2 diabetes mellitus and established atherosclerotic CVD were randomised to receive ertugliflozin 5 mg or 15 mg (observations from both doses were pooled), or matching placebo, added on to existing treatment. ...CON …
METHODS: Individuals with type 2 diabetes mellitus and established atherosclerotic CVD were randomised to receiv …
247 results

Searches related to "ertugliflozin type 2 diabetes"